Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas (TMZ-Cap)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03930771
Recruitment Status : Recruiting
First Posted : April 29, 2019
Last Update Posted : May 30, 2019
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
This is an open label study to assess the efficacy of capecitabine (CAP) and temozolomide (TMZ) in recurrent pituitary adenomas. There will be a safety run-in of at least three patients to establish any dose limiting toxicities. Enrolled patients will receive treatment in 28-day cycles: capecitabine 1500mg/m2 per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14 and oral temozolomide 150 to 200 mg/m2 on days 10 through 14. This will be followed by 14 days off treatment. MRI imaging will be completed after every two cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

Condition or disease Intervention/treatment Phase
Recurrent Pituitary Adenomas Drug: Capecitabine Drug: Temozolomide Phase 2

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas
Actual Study Start Date : May 21, 2019
Estimated Primary Completion Date : September 1, 2023
Estimated Study Completion Date : September 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: All Patients

All subjects will receive:

  1. Capecitabine (oral 5-Fluorouracil) 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
  2. Temozolomide (second generation alkylating agent) 150 to 200 mg/m2 orally on days 10 through 14.

After completion of 6 cycles, patients achieving a complete or partial tumor response may continue to receive capecitabine temozolomide at the investigator's discretion in the absence of disease progression or unacceptable toxicity. Patients will be monitored for six months after they come off the study (either after completing 6 cycles or in setting of disease progression or unacceptable toxicity).

Drug: Capecitabine
1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.

Drug: Temozolomide
150 to 200 mg/m2 orally on days 10 through 14.




Primary Outcome Measures :
  1. Number of subjects with Radiographic Response, as defined by the RECIST criteria. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Effect of the CAP and TMZ combination on pituitary function, measured by changes in pituitary hormone secretion in patients [ Time Frame: At baseline and every 8 weeks, up to 6 months ]
    Serum prolactin, IGF-1, ACTH, FSH, LH and TSH levels are used to assess changes in pituitary hormone function. These tests will only be repeated if found to be abnormal at baseline.

  2. Safety, as measured by the number of subjects with at least one AE [ Time Frame: 6 months ]
  3. Tolerability of the TMZ and Capecitabine combination, as measured by number of participants with a dose-limiting toxicity [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria::

  • Male or female ≥ 18 years of age.
  • Patients with nonfunctioning tumors must have histologically confirmed pituitary adenoma. Patients with functioning tumors do not require surgery if there is clear diagnosis of functioning pituitary adenomas established based on endocrine evaluation.
  • Karnofsky performance status ≥ 70%.
  • Life expectancy of greater than six months.
  • Residual or recurrent pituitary adenoma ≥1cm in maximal diameter on MRI Brain; patient must have received at least one prior therapy, such as surgery, radiation and/or medical therapy.
  • Patients must have normal organ and marrow function as defined below. NOTE: Laboratory values must be taken within 7 days prior to chemotherapy administration. Transfusions and/or growth factor support may not be used to meet this criteria):
  • Platelet count ≥ 100 × 109/L.
  • Hemoglobin ≥ 9 g/dL.
  • WBC ≥ 3 × 109/L
  • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
  • Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 x ULN if Gilbert's disease is documented.
  • Aspartate transaminase (AST) ≤ 2.5 ULN.
  • Alanine transaminase (ALT) ≤ 2.5 ULN.
  • Serum creatinine ≤ 1.5 × ULN OR creatinine clearance≥60mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
  • Patients must be able to undergo a MRI Brain/Pituitary
  • For women of child-bearing potential and for men with partners of child-bearing potential, subject must agree to take contraceptive measures for duration of treatment and at least 6 months after the last dose of chemotherapy.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Prior temozolomide and/or capecitabine therapy for treatment of the pituitary tumor.
  • Other active malignancy outside of nonmelanoma skin cancer (patients in remission and with prior treatment more than two years ago will be accepted into trial).
  • Clinically significant renal, hematologic or hepatic abnormalities.
  • Use of Vitamin K antagonists such as warfarin (concentrations may be altered by concomitant use of capecitabine)
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics & psychiatric illness/social situations that would limit compliance with study requirements
  • History of deficient dihydropyrimidine dehydrogenase activity.
  • History of immunodeficiency.
  • Patients who are taking any other concurrent investigational therapy.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had prior radiation treatment in the last six months
  • Patients who have had prior pituitary surgery within the last two months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03930771


Contacts
Layout table for location contacts
Contact: Monique Tarrant, RN (646) 962-2185 mot2013@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10065
Contact: June Greenberg       jdg2002@med.cornell.edu   
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Rajiv Magge, B.S Weill Medical College of Cornell University

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03930771     History of Changes
Other Study ID Numbers: 1809019558
First Posted: April 29, 2019    Key Record Dates
Last Update Posted: May 30, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pituitary Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Brain Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Supratentorial Neoplasms
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Adenoma
Pituitary Diseases
Hypothalamic Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Capecitabine
Temozolomide
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents